Tumour cell responses to new fibroblast growth factor receptor tyrosine kinase inhibitors and identification of a gatekeeper mutation in FGFR3 as a mechanism of acquired resistance (original) (raw)
Klint P, Claesson-Welsh L . Signal transduction by fibroblast growth factor receptors. Front Biosci 1999; 4: D165–D177. ArticleCASPubMed Google Scholar
Eswarakumar VP, Lax I, Schlessinger J . Cellular signaling by fibroblast growth factor receptors. Cytokine Growth Factor Rev 2005; 16: 139–149. ArticleCASPubMed Google Scholar
Ornitz DM, Marie PJ . FGF signaling pathways in endochondral and intramembranous bone development and human genetic disease. Genes Dev 2002; 16: 1446–1465. ArticleCASPubMed Google Scholar
Pardo OE, Arcaro A, Salerno G, Raguz S, Downward J, Seckl MJ et al. Fibroblast growth factor-2 induces translational regulation of Bcl-XL and Bcl-2 via a MEK-dependent pathway. J Biol Chem 2002; 277: 12040–12046. ArticleCASPubMed Google Scholar
Jeffers M, LaRochelle WJ, Lichenstein HS . Fibroblast growth factors in cancer: therapeutic possibilities. Expert Opin Ther Targets 2002; 6: 469–482. ArticleCASPubMed Google Scholar
Knights V, Cook SJ . De-regulated FGF receptors as therapeutic targets in cancer. Pharmacol Ther 2010; 125: 105–117. ArticleCASPubMed Google Scholar
Keats JJ, Reiman T, Belch AR, Pilarski LM . Ten years and counting: so what do we know about t(4;14)(p16;q32) multiple myeloma. Leuk Lymphoma 2006; 47: 2289–2300. ArticleCASPubMed Google Scholar
Jang JH, Shin KH, Park JG . Mutations in fibroblast growth factor receptor 2 and fibroblast growth factor receptor 3 genes associated with human gastric and colorectal cancers. Cancer Res 2001; 61: 3541–3543. CASPubMed Google Scholar
Ray ME, Yang ZQ, Albertson D, Kleer CG, Washburn JG, Macoska JA et al. Genomic and expression analysis of the 8p11-12 amplicon in human breast cancer cell lines. Cancer Res 2004; 64: 40–47. ArticleCASPubMed Google Scholar
Billerey C, Chopin D, Aubriot-Lorton MH, Ricol D, Gil Diez de Medina S, Van Rhijn B et al. Frequent FGFR3 mutations in papillary non-invasive bladder (pTa) tumors. Am J Pathol 2001; 158: 1955–1959. ArticleCASPubMedPubMed Central Google Scholar
Reiter A, Sohal J, Kulkarni S, Chase A, Macdonald DH, Aguiar RC et al. Consistent fusion of ZNF198 to the fibroblast growth factor receptor-1 in the t(8;13)(p11;q12) myeloproliferative syndrome. Blood 1998; 92: 1735–1742. CASPubMed Google Scholar
Moffa AB, Tannheimer SL, Ethier SP . Transforming potential of alternatively spliced variants of fibroblast growth factor receptor 2 in human mammary epithelial cells. Mol Cancer Res 2004; 2: 643–652. CASPubMed Google Scholar
Gavine PR, Mooney L, Kilgour E, Thomas AP, Al-Kadhimi K, Beck S et al. AZD4547: an orally bioavailable, potent and selective inhibitor of the fibroblast growth factor receptor tyrosine kinase family. Cancer Res 2012; 72: 2045–2056. ArticleCASPubMed Google Scholar
Klinowska T, Gavine PR, Mooney L, Parveen N, Al-Kadhimi K, Thomas A et al. The characterization of novel, potent and selective small molecule inhibitors of the FGFR tyrosine kinase in vitro and in vivo. Gordon Research Conference 2–7 March 2008; Lucca, Italy. Google Scholar
Kahan C, Seuwen K, Meloche S, Pouysségur J . Coordinate, biphasic activation of p44 mitogen-activated protein kinase and S6 kinase by growth factors in hamster fibroblasts. Evidence for thrombin-induced signals different from phosphoinositide turnover and adenylylcyclase inhibition. J Biol Chem 1992; 267: 13369–13375. CASPubMed Google Scholar
Chesi M, Brents LA, Ely SA, Bais C, Robbiani DF, Mesri EA et al. Activated fibroblast growth factor receptor 3 is an oncogene that contributes to tumor progression in multiple myeloma. Blood 2001; 97: 729–736. ArticleCASPubMed Google Scholar
Trudel S, Ely S, Farooqi Y, Affer M, Robbiani DF, Chesi M et al. Inhibition of fibroblast growth factor receptor 3 induces differentiation and apoptosis in t(4;14) myeloma. Blood 2004; 103: 3521–3528. ArticleCASPubMed Google Scholar
Lombardi L, Poretti G, Mattioli M, Fabris S, Agnelli L, Bicciato S et al. Molecular characterization of human multiple myeloma cell lines by integrative genomics: insights into the biology of the disease. Genes Chromosomes Cancer 2007; 46: 226–238. ArticleCASPubMed Google Scholar
Ronchetti D, Greco A, Compasso S, Colombo G, Dell'Era P, Otsuki T et al. Deregulated FGFR3 mutants in multiple myeloma cell lines with t(4;14): comparative analysis of Y373C, K650E and the novel G384D mutations. Oncogene 2001; 20: 3553–3562. ArticleCASPubMed Google Scholar
Kimura T, Suzuki H, Ohashi T, Asano K, Kiyota H, Eto Y . The incidence of thanatophoric dysplasia mutations in FGFR3 gene is higher in low-grade or superficial bladder carcinomas. Cancer 2001; 92: 2555–2561. ArticleCASPubMed Google Scholar
Tomlinson DC, Baldo O, Harnden P, Knowles MA . FGFR3 protein expression and its relationship to mutation status and prognostic variables in bladder cancer. J Pathol 2007; 213: 91–98. ArticleCASPubMedPubMed Central Google Scholar
Al-Ahmadie HA, Iyer G, Janakiraman M, Lin O, Heguy A, Tickoo SK et al. Somatic mutation of fibroblast growth factor receptor-3 (FGFR3) defines a distinct morphological subtype of high-grade urothelial carcinoma. J Pathol 2011; 224: 270–279. ArticleCASPubMedPubMed Central Google Scholar
Tomlinson DC, Hurst CD, Knowles MA . Knockdown by shRNA identifies S249C mutant FGFR3 as a potential therapeutic target in bladder cancer. Oncogene 2007; 26: 5889–5899. ArticleCASPubMedPubMed Central Google Scholar
Turner N, Lambros MB, Horlings HM, Pearson A, Sharpe R, Natrajan R et al. Integrative molecular profiling of triple negative breast cancers identifies amplicon drivers and potential therapeutic targets. Oncogene 2010; 29: 2013–2023. ArticleCASPubMedPubMed Central Google Scholar
Sun S, Jiang Y, Zhang G, Song H, Zhang X, Zhang Y et al. Increased expression of fibroblastic growth factor receptor 2 is correlated with poor prognosis in patients with breast cancer. J Surg Oncol 2011; 105: 773–779. ArticlePubMed Google Scholar
Tannheimer SL, Rehemtulla A, Ethier SP . Characterization of fibroblast growth factor receptor 2 overexpression in the human breast cancer cell line SUM-52PE. Breast Cancer Res 2000; 2: 311–320. ArticleCASPubMedPubMed Central Google Scholar
Hattori Y, Odagiri H, Nakatani H, Miyagawa K, Naito K, Sakamoto H et al. K-sam, an amplified gene in stomach cancer, is a member of the heparin-binding growth factor receptor genes. Proc Natl Acad Sci USA 1990; 87: 5983–5987. ArticleCASPubMedPubMed Central Google Scholar
Kuniyasu H, Yasui W, Kitadai Y, Yokozaki H, Ito H, Tahara E . Frequent amplification of the c-met gene in scirrhous type stomach cancer. Biochem Biophys Res Commun 1992; 189: 227–232. ArticleCASPubMed Google Scholar
Tsujimoto H, Sugihara H, Hagiwara A, Hattori T . Amplification of growth factor receptor genes and DNA ploidy pattern in the progression of gastric cancer. Virchows Arch 1997; 431: 383–389. ArticleCASPubMed Google Scholar
Mor O, Ranzani GN, Ravia Y, Rotman G, Gutman M, Manor A et al. DNA amplification in human gastric carcinomas. Cancer Genet Cytogenet 1993; 65: 111–114. ArticleCASPubMed Google Scholar
Kunii K, Davis L, Gorenstein J, Hatch H, Yashiro M, Di Bacco A et al. FGFR2-amplified gastric cancer cell lines require FGFR2 and Erbb3 signaling for growth and survival. Cancer Res 2008; 68: 2340–2348. ArticleCASPubMed Google Scholar
Wheeler DL, Dunn EF, Harari PM . Understanding resistance to EGFR inhibitors-impact on future treatment strategies. Nat Rev Clin Oncol 2010; 7: 493–507. ArticleCASPubMedPubMed Central Google Scholar
Milojkovic D, Apperley J . Mechanisms of resistance to imatinib and second- generation tyrosine inhibitors in chronic myeloid leukemia. Clin Cancer Res 2009; 15: 7519–7527. ArticleCASPubMed Google Scholar
Hammerman PS, Janne PA, Johnson BE . Resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. Clin Cancer Res 2009; 15: 7502–7509. ArticleCASPubMed Google Scholar
Ley R, Balmanno K, Hadfield K, Weston C, Cook SJ . Activation of the ERK1/2 signaling pathway promotes phosphorylation and proteasome-dependent degradation of the BH3-only protein, Bim. J Biol Chem 2003; 278: 18811–18816. ArticleCASPubMed Google Scholar
Ewings KE, Hadfield-Moorhouse K, Wiggins CM, Wickenden JA, Balmanno K, Gilley R et al. ERK1/2-dependent phosphorylation of BimEL promotes its rapid dissociation from Mcl-1 and Bcl-xL. EMBO J 2007; 26: 2856–2867. ArticleCASPubMedPubMed Central Google Scholar
Azam M, Seeliger MA, Gray NS, Kuriyan J, Daley GQ . Activation of tyrosine kinases by mutation of the gatekeeper threonine. Nat Struct Mol Biol 2008; 15: 1109–1118. ArticleCASPubMedPubMed Central Google Scholar
Daub H, Specht K, Ullrich A . Strategies to overcome resistance to targeted protein kinase inhibitors. Nat Rev Drug Discov 2004; 3: 1001–1010. ArticleCASPubMed Google Scholar
Azam M, Daley GQ . Anticipating clinical resistance to target-directed agents: the BCR-ABL paradigm. Mol Diagn Ther 2006; 10: 67–76. ArticleCASPubMed Google Scholar
Mohammadi M, Froum S, Hamby JM, Schroeder MC, Panek RL, Lu GH et al. Crystal structure of an angiogenesis inhibitor bound to the FGF receptor tyrosine kinase domain. EMBO J 1998; 17: 5896–5904. ArticleCASPubMedPubMed Central Google Scholar
Qing J, Du X, Chen Y, Chan P, Li H, Wu P et al. Antibody-based targeting of FGFR3 in bladder carcinoma and t(4;14)-positive multiple myeloma in mice. J Clin Invest 2009; 119: 1216–1229. ArticleCASPubMedPubMed Central Google Scholar
Squires M, Ward G, Saxty G, Berdini V, Cleasby A, King P et al. Potent, selective inhibitors of fibroblast growth factor receptor define fibroblast growth factor dependence in preclinical cancer models. Mol Cancer Ther 2011; 10: 1542–1552. ArticleCASPubMed Google Scholar
Trudel S, Li ZH, Wei E, Wiesmann M, Chang H, Chen C et al. CHIR-258, a novel, multitargeted tyrosine kinase inhibitor for the potential treatment of t(4;14) multiple myeloma. Blood 2005; 105: 2941–2948. ArticleCASPubMed Google Scholar
Lamont FR, Tomlinson DC, Cooper PA, Shnyder SD, Chester JD, Knowles MA . Small molecule FGF receptor inhibitors block FGFR-dependent urothelial carcinoma growth in vitro and in vivo. Br J Cancer 2011; 104: 75–82. ArticleCASPubMed Google Scholar
Jebar AH, Hurst CD, Tomlinson DC, Johnston C, Taylor CF, MA Knowles . FGFR3 and Ras gene mutations are mutually exclusive genetic events in urothelial cell carcinoma. Oncogene 2005; 24: 5218–5225. ArticleCASPubMed Google Scholar
Normanno N, Tejpar S, Morgillo F, De Luca A, Van Cutsem E, Ciardiello F . Implications for KRAS status and EGFR-targeted therapies in metastatic CRC. Nat Rev Clin Oncol 2009; 6: 519–527. ArticleCASPubMed Google Scholar
Zhou W, Hur W, McDermott U, Dutt A, Xian W, Ficarro SB et al. A structure-guided approach to creating covalent FGFR inhibitors. Chem Biol 2010; 17: 285–295. ArticleCASPubMedPubMed Central Google Scholar
Huynh H, Ngo VC, Fargnoli J, Ayers M, Soo KC, Koong HN et al. Brivanib alaninate, a dual inhibitor of vascular endothelial growth factor receptor and fibroblast growth factor receptor tyrosine kinases, induces growth inhibition in mouse models of human hepatocellular carcinoma. Clin Cancer Res 2008; 14: 6146–6153. ArticleCASPubMed Google Scholar
Hilberg F, Roth GJ, Krssak M, Kautschitsch S, Sommergruber W, Tontsch-Grunt U et al. BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy. Cancer Res 2008; 68: 4774–4782. ArticleCASPubMed Google Scholar
Radomska HS, Bassères DS, Zheng R, Zhang P, Dayaram T, Yamamoto Y et al. Block of C/EBP alpha function by phosphorylation in acute myeloid leukemia with FLT3 activating mutations. J Exp Med 2006; 203: 371–381. ArticleCASPubMedPubMed Central Google Scholar
Pabst T, Mueller BU, Harakawa N, Schoch C, Haferlach T, Behre G et al. AML1-ETO downregulates the granulocytic differentiation factor C/EBPalpha in t(8;21) myeloid leukemia. Nat Med 2001; 7: 444–451. ArticleCASPubMed Google Scholar
Kawano M, Hirano T, Matsuda T, Taga T, Horii Y, Iwato K et al. Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas. Nature 1988; 332: 83–85. ArticleCASPubMed Google Scholar
Binato R, Mencalha A, Pizzatti L, Scholl V, Zalcberg I, Abdelhay E . RUNX1T1 is overexpressed in imatinib mesylate-resistant cells. Mol Med Rep 2009; 2: 657–661. ArticleCASPubMed Google Scholar
Todd DE, Densham RM, Molton SA, Balmanno K, Newson C, Weston CR et al. ERK1/2 and p38 cooperate to induce a p21CIP1-dependent G1 cell cycle arrest. Oncogene 2004; 23: 3284–3295. ArticleCASPubMed Google Scholar
Davies BR, Logie A, McKay JS, Martin P, Steele S, Jenkins R et al. AZD6244 (ARRY-142886), a potent inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 1/2 kinases: mechanism of action in vivo, pharmacokinetic/pharmacodynamic relationship, and potential for combination in preclinical models. Mol Cancer Ther 2007; 6: 2209–2219. ArticleCASPubMed Google Scholar
Waterhouse AM, Procter JB, Martin DMA, Clamp M, Barton GJ . Jalview Version 2 a multiple sequence alignment editor and analysis workbench. Bioinformatics 2009; 25: 1189–1191. ArticleCASPubMedPubMed Central Google Scholar
Benjamini Y, Hochberg Y . Controlling the false discovery rate: a practical and powerful approach to multiple testing. J Roy Statist Soc Ser B (Methodological) 1995; 57: 289–300. Google Scholar
Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, De Paepe A et al. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol 2002; 3: : RESEARCH0034. Article Google Scholar